Kilitch Drugs India Ltd Stock Price Today (NSE: KILITCH)

Kilitch Drugs India Ltd

178.602.43 (1.34%)
Market Open

Fundamental Score

...

Kilitch Drugs India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Kilitch Drugs India Ltd share price today is 178.60, down 1.34% on NSE/BSE as of 23 June 2026. Kilitch Drugs India Ltd (KILITCH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 599.59 (Cr). The 52-week high for KILITCH share price is 500.00 and the 52-week low is 117.25. At a P/E ratio of 21.74x, KILITCH is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.61% and a debt-to-equity ratio of 0.31.

Kilitch Drugs India Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
197.00
Low
145.50
Volume
1.6L
Change
+18.31%

Kilitch Drugs India Ltd share price chart: 18.31% return over the past month. 52-week high ₹500.00, 52-week low ₹117.25.

Kilitch Drugs India Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
181.82185.23174.02178.601.48L (Cr)
184.99187.92179.00181.0380.30K (Cr)
183.34190.80178.90182.391.38L (Cr)
180.00184.95178.00182.0260.62K (Cr)
186.44187.80176.51180.611.92L (Cr)
188.90197.00184.10185.181.58L (Cr)
183.97187.28181.10182.2789.62K (Cr)
184.20188.80179.83183.061.77L (Cr)
175.01188.00172.75183.803.28L (Cr)
167.60177.59166.06174.371.62L (Cr)

Kilitch Drugs India Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
184.99187.92174.02178.60-3.45%
154.02197.00145.50182.39+18.42%
126.00163.40122.91154.02+22.24%
320.00330.00117.25124.45-61.11%
339.00406.00311.10323.50-4.57%
346.85368.20308.60313.95-9.49%
343.00373.90321.15350.20+2.10%
390.80402.75338.45342.10-12.46%
338.05439.00337.75388.35+14.88%
339.00383.40333.05337.95-0.31%
445.00454.45332.15339.30-23.75%
450.90500.00411.01441.00-2.20%

Returns & Performance

Poor

Return on Equity (ROE)

12.61%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

15.67%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

13.27%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Kilitch Drugs India Ltd Valuation Check

Excellent

Price to Earnings (P/E)

21.74x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

63.77%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-4.99%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

3.05%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

30.06%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

156.54%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

158.61%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.31x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

6.85x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-31.59 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Kilitch Drugs India Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of KILITCH across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Excellent ROCE Performance (15.67%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 21.74 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Consistent Growth Track Record (30.06% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (156.54% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (158.61% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Interest Coverage (6.85x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (63.77%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Negative Free Cash Flow (₹-31.59 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Kilitch Drugs India Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Kilitch Drugs India Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
50.2/100
179
₹599.59
21.7
Average
12.61%
Average
15.67%
Good
0.3
Excellent
158.61%
Excellent
30.06%
Excellent
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

Kilitch Drugs India Ltd PE Ratio History

Historical price-to-earnings ratio for KILITCH — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202516.60₹350.2021.1x
FY 20249.17₹326.2035.6x
FY 20236.71₹369.3055x
FY 20224.73₹155.6532.9x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Kilitch Drugs India Ltd Dividend History

Annual cash dividends paid by KILITCH — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20221.20 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Kilitch Drugs India Ltd Quarterly Performance

Latest quarterly metrics for KILITCH — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

3.05%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-4.99%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

30.06%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

158.61%

Compounded annual net profit growth over 5 years

Kilitch Drugs India Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for KILITCH — calculated from daily price history

68RSI 14
Neutral — RSI 68

Momentum is balanced — neither overbought nor oversold.

SMA 50
178
▲ Price above SMA 50 — Short-term bullish
SMA 200
312
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
155K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Kilitch Drugs India Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Kilitch Drugs India Ltd (KILITCH) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Kilitch Drugs India Ltd

About KILITCH (Kilitch Drugs India Ltd)

Kilitch Drugs India Ltd is a pharmaceutical enterprise carving a distinct niche in the global healthcare landscape. Focused on manufacturing and distributing a diverse portfolio of... specialized medications, Kilitch is committed to addressing critical healthcare needs worldwide. The company’s core strength lies in its state-of-the-art manufacturing facilities, meticulously designed to adhere to the stringent international quality standards. This focus enables the production of high-quality pharmaceuticals that are both safe and efficacious. Kilitch Drugs leverages its technical prowess and in-depth understanding of pharmaceutical science to deliver innovative solutions across various therapeutic segments. The company’s unwavering dedication to quality and its global reach positions it as a reliable partner in the pharmaceutical industry. Kilitch's product offerings are strategically curated to cater to a broad spectrum of medical requirements. The company specializes in sterile formulations, offering a wide range of injectable products including liquid and powder forms. These formulations are vital for delivering medications directly into the bloodstream, ensuring rapid and effective treatment. In addition to injectables, Kilitch provides advanced nasal delivery systems, enabling targeted administration of drugs through the nasal passages. Kilitch’s product line extends further to include topical formulations, addressing skin and surface-level ailments. This multi-faceted approach allows Kilitch to contribute to diverse therapeutic areas, strengthening its impact on global healthcare. Kilitch Drugs India Ltd. actively pursues opportunities for international expansion, strategically establishing its presence in key markets across the globe. By building strong distribution networks and fostering collaborations with local partners, Kilitch is successfully extending the reach of its pharmaceutical products. The company’s commitment to providing affordable, high-quality medications aligns with the growing demand for accessible healthcare solutions worldwide. Kilitch Drugs is poised to capitalize on emerging market trends and expanding its global footprint through strategic partnerships and a focus on product innovation. As Kilitch continues to evolve and grow, the company will maintain its unwavering commitment to improving patient outcomes.

Company Details

Symbol:KILITCH
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mukund Prataprai Mehta B.Com., LL.B.
Executive Chairman & MD
Ms. Mira Bhavin Mehta
MD & Director
Mr. Bhavin Mukund Mehta B.Pharm.
Whole-time Director

Corporate Events

Recent
Ex-Dividend Date

KILITCH Share Price: Frequently Asked Questions

What is the current share price of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd (KILITCH) trades at ₹178.60 on NSE and BSE. Market cap ₹599.59 (Cr). Educational data only.

What is the P/E ratio of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd has a P/E of 21.74x vs industry average 31.77x.

What is the Bull Run score for Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd has a Bull Run score of 50.2/100 based on 25+ financial parameters.

Does Kilitch Drugs India Ltd pay dividends?

Kilitch Drugs India Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd has ROE of 12.61%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Kilitch Drugs India Ltd?

Kilitch Drugs India Ltd has debt-to-equity of 0.31.

Is Kilitch Drugs India Ltd a good investment?

Bull Run gives Kilitch Drugs India Ltd a score of 50.2/100. This is not investment advice — consult a SEBI-registered advisor.